In This Article:
NeoGenomics (NASDAQ:NEO) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$168.0m (up 7.5% from 1Q 2024).
-
Net loss: US$25.9m (loss narrowed by 4.2% from 1Q 2024).
-
US$0.20 loss per share (improved from US$0.21 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeoGenomics EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 3.4%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are down 23% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for NeoGenomics that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.